10-Q: PharmaCyte Biotech Reports Q2 Loss, Nasdaq Delisting Risk

PharmaCyte Biotech, Inc. reported a significant net loss for the second quarter and six months ended October 31, 2025, while facing a Nasdaq minimum bid price non-compliance notice and ongoing FDA clinical hold challenges.

Summary

• Net loss attributable to common stockholders was $(8,416,610) for the three months ended October 31, 2025, compared to $(2,958,875) for the same period in 2024.
• Net loss attributable to common stockholders was $(16,776,706) for the six months ended October 31, 2025, a significant increase from a net income of $17,628,632 for the same period in 2024.
• Cash and cash equivalents increased slightly to $15.4 million as of October 31, 2025, from $15.2 million at April 30, 2025, with current cash projected to be $20.9 million as of the filing date.
• The company received a Nasdaq notice on December 1, 2025, for non-compliance with the minimum bid price rule ($1.00 per share), with a compliance date of June 1, 2026.
• The FDA clinical hold on the Investigational New Drug Application (IND) for locally advanced, inoperable pancreatic cancer (LAPC) remains in effect, with ongoing efforts to address FDA requests and seek to forego a large animal study.
• A private placement of Series C convertible preferred stock and warrants in August 2025 generated $7 million in gross proceeds.
• The company settled a legal dispute with H.C. Wainwright & Co., LLC for $1.55 million and issued warrants.
• Research and development costs increased to $141,085 for the three months and $236,242 for the six months ended October 31, 2025, compared to the prior year.
• Total liabilities increased dramatically to $19,422,384 at October 31, 2025, from $3,277,284 at April 30, 2025, primarily due to warrant and derivative liabilities.

Sentiment

Score: 2

Explanation: The company faces significant financial losses, a Nasdaq delisting threat, and persistent regulatory hurdles with the FDA clinical hold. While some technical studies are progressing, the overall financial health and operational timeline are highly concerning, indicating substantial downside risk.

Positives

• Successful completion of required product stability studies for the pancreatic cancer product candidate.
• Successful completion of various additional studies requested by the FDA, including a stability study on cells from the Master Cell Bank.
• Determination and confirmation of the exact sequence of the cytochrome P450 2B1 gene, confirming genes are intact and genetically stable.
• Eight out of ten requested biocompatibility studies have been successfully completed.
• Systemic toxicity testing showed no evidence of toxicity and confirmed the capsule material is bioinert.
• The company raised $7 million in gross proceeds from a Series C private placement in August 2025.
• The Femasys Note was settled in full for $5 million cash in November 2025, along with 379,747 Femasys common stock shares for accrued interest.
• Cash and cash equivalents are projected to be $20.9 million as of the filing date, sufficient for at least the next twelve months.
• Stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing available shares by 2,250,000.
• Stockholders approved the issuance of shares underlying Series C Preferred Stock and Warrants to comply with Nasdaq Listing Rule 5635(d), allowing conversion into common stock and adjusting the conversion floor price to $0.19.

Negatives

• Net loss attributable to common stockholders significantly widened to $(8,416,610) for the three months ended October 31, 2025, from $(2,958,875) in the prior year.
• For the six months ended October 31, 2025, the company reported a net loss of $(16,776,706), a substantial decline from a net income of $17,628,632 in the same period last year.
• The company received a Nasdaq notice of non-compliance for failing to maintain a minimum bid price of $1.00 per share.
• The FDA clinical hold on the LAPC IND remains in effect, requiring additional preclinical studies and information.
• The Board has curtailed spending on development programs, including pre-clinical and clinical activities, pending a review, which may cause further delays or termination of programs dependent on SG Austria.
• Know-how relating to the Cell-in-a-Box technology solely resides with SG Austria, and all licensed patents have expired, creating potential misalignment of incentives.
• Significant losses from changes in fair value of warrant liabilities ($(10,474,000) for Q2 2025) and warrant assets (Femasys: $(726,000) for Q2 2025; QCLS: $(191,000) for six months 2025).
• Unrealized loss on marketable securities of $(165,126) for the six months ended October 31, 2025.
• Issuance costs of $(1,234,553) and a loss on issuance of Series C convertible preferred stock of $(215,000) were incurred.
• Ongoing material weaknesses in internal control over financial reporting due to insufficient segregation of duties of the Chief Financial Officer and insufficient management review controls.
• The company expects to need additional capital to complete a clinical trial for pancreatic cancer, which could be dilutive or involve restrictive covenants.
• The conversion price of Series B Warrants was adjusted from $4.00 to $0.95 per share due to anti-dilution provisions, increasing the number of shares issuable upon exercise.

Risks

• Inability to obtain FDA approval for the Investigational New Drug Application (IND) after completing requested studies and responding to the clinical hold, preventing commencement of the planned clinical trial for LAPC.
• Potential for preclinical studies and clinical trials to indicate that technologies and product candidates are unsafe or ineffective.
• Dependence on third parties for conducting preclinical studies and clinical trials.
• Difficulties and expenses associated with obtaining and maintaining regulatory approval for product candidates.
• Material adverse impact from the coronavirus pandemic on business, including the planned clinical trial.
• Inability to comply with Nasdaq Capital Market listing requirements, leading to potential delisting of common stock.
• The Board's review of development programs and relationship with SG Austria, including expired licensed patents and SG Austria solely possessing know-how, could lead to delays or termination of programs dependent on SG Austria.
• Curtailment of spending on programs pending Board review may cause additional delays.
• Need for additional capital to complete a clinical trial for pancreatic cancer, with potential for dilutive equity financing or restrictive debt covenants.
• Inability to access capital on a timely basis, which would materially adversely affect business, financial condition, and results of operations.
• Operating in an industry subject to rapid technological change, competition, and government regulation.
• Potential for cellular and humoral immune reactivity against the heterologous rat CYP2B1 protein and induction of autoimmune-mediated toxicities in the study population.
• Insufficient segregation of duties of the Chief Financial Officer and insufficient management review controls, constituting material weaknesses in internal control over financial reporting.
• Delisting from Nasdaq could lead to limited market quotations, reduced liquidity, 'penny stock' designation, limited news/analyst coverage, and decreased ability to raise future financing.

Future Outlook

The company expects its current cash and cash equivalents of approximately $20.9 million (inclusive of the $5 million received from Femasys Note maturity) as of the filing date to be sufficient for at least the next twelve months. However, additional capital will be needed to complete a clinical trial for pancreatic cancer, which may involve dilutive equity financing or restrictive debt. The company is actively working to address the FDA clinical hold, including seeking permission to forego a large animal study, and is in ongoing dialogue with SG Austria to prepare for next steps and update the drug master file. The Strategic Scientific Committee and Board are reviewing development programs and the relationship with SG Austria, which may lead to a new framework or reevaluation of programs dependent on SG Austria. The company intends to monitor its common stock bid price and consider all options, including a reverse stock split, to regain Nasdaq compliance.

Management Comments

• We believe that the technology upon which the LAPC treatment will be based, intra-arterial chemotherapy, has been used in five clinical trials in humans. Our position is that the data available from these human clinical trials supersedes large animal study data.
• The treatment may not be a treatment of pancreatic cancer, but a method of improving and possibly enabling complete surgical resection of the tumor.
• We are waiting for the FDAs responses and hope the FDA will accept that the LAPC treatment now meets manufacturing standard requirements, which have significantly improved since the clinical hold was first placed.
• We intend to actively monitor the closing bid price of our Common Stock and will consider all available options to regain compliance with the Bid Price Rule, including, if appropriate, implementing a reverse stock split, subject to stockholder approval.
• We do not believe there are factors which will cause materially different amounts to be reported than those presented in this Report. We aim to assess this regularly to provide accurate information to our shareholders.

Industry Context

The biotechnology industry is characterized by rapid technological change, intense competition, and stringent government regulation, particularly from the FDA. PharmaCyte Biotech's focus on cellular therapies for cancer, specifically LAPC, places it in a high-risk, high-reward segment. The ongoing clinical hold and the need for significant capital to advance trials are common challenges for early-stage biotech companies. The reliance on a proprietary technology (Cell-in-a-Box) licensed from SG Austria, where patents have expired and know-how resides with the licensor, highlights a significant intellectual property and operational risk that is not uncommon in complex licensing agreements within the industry. The company's strategy to improve surgical resection outcomes for LAPC aligns with a broader trend in oncology to combine therapies for better patient outcomes. The Nasdaq delisting notice is a common issue for smaller, pre-revenue biotech firms whose stock prices can be volatile and fall below minimum thresholds.

Comparison to Industry Standards

• The company's situation with an FDA clinical hold requiring additional preclinical studies (e.g., large animal study) is a standard regulatory hurdle in drug development. The company's argument that human clinical trial data for intra-arterial chemotherapy should supersede large animal study data is a specific point of contention with the FDA, which often requires specific preclinical data for novel drug-device combinations or cell therapies, even if components have been used before.
• The company's reliance on a licensed technology (Cell-in-a-Box) where the licensor (SG Austria) holds the know-how and patents have expired presents a significant intellectual property risk that is below industry best practices for long-term control over core technology. Leading biotech companies typically aim for strong proprietary patent portfolios and in-house expertise.
• The need for additional capital to complete clinical trials is standard for pre-revenue biotech companies. However, the significant losses and the Nasdaq delisting risk could make future capital raises more challenging and dilutive compared to more stable industry peers.
• The material weaknesses in internal control over financial reporting (insufficient segregation of duties, insufficient management review) are below industry standards for public companies, indicating governance and operational deficiencies that need urgent remediation.

Corporate Governance

Legal Proceedings

• On May 16, 2025, the company entered into a settlement and release agreement with H.C. Wainwright & Co., LLC, resolving a breach of contract complaint filed on December 4, 2023.
• The settlement required a payment of $1.55 million, consisting of an initial $1.25 million paid on May 20, 2025, and twelve equal payments of $25,000.
• As part of the settlement, the company issued warrants (First Warrant Issuance and Additional Warrants) to purchase common stock. The exercise price of these warrants was adjusted to $0.95 per share on August 19, 2025, due to anti-dilution provisions.
• No other material litigation against officers or directors is known or contemplated.

Related Party Transactions

• The company owns 13.9% equity in SG Austria, which was fully impaired as of April 30, 2024.
• No products or services were purchased from SG Austria or its subsidiaries (Austrianova, Austrianova Thailand) during the three and six months ended October 31, 2025 and 2024.
• The Vin-de-Bona Consulting Agreement, with a company owned by Prof. Gnzburg (Chairman of Austrianova) and Dr. Salmons (CEO/President of Austrianova), incurred no expenses for the three and six months ended October 31, 2025, but $2,670 and $5,280 for the same periods in 2024, respectively.
• The company's Chief Executive Officer was appointed to the Femasys board of directors.
• The company's Chief Executive Officer serves as the executive chairman of QCLS.
• Service agreements related to the IND clinical hold have an estimated total remaining cost of $543,000, of which approximately $157,000 is with related parties (SG Austria and its subsidiaries).

Stakeholder Impact

• Shareholders face significant dilution risk from future capital raises and warrant exercises, potential negative impact on share price due to Nasdaq delisting threat, and uncertainty regarding the future of the core pancreatic cancer program.
• Employees may be impacted by the curtailment of spending on programs, potentially affecting job security or project progression.
• Future patients are affected by delays in addressing the FDA clinical hold, meaning the pancreatic cancer treatment is not progressing towards market availability.
• Creditors may have concerns about the company's long-term solvency due to increased liabilities, particularly warrant and derivative liabilities, despite current cash projections.
• Partners like SG Austria could see impacts on future collaborations and revenue streams depending on the outcome of the Board's review of the relationship and potential new frameworks.

Next Steps

• Address FDA requests to lift the clinical hold on the IND for LAPC, including potentially foregoing a large animal study.
• Continue dialogue with SG Austria to prepare for next steps and add requested information to the drug master file.
• Complete Micro-Compression and Swelling Testing, Break Force and Glide Testing, Capsules Compatibility with Delivery System, and CypCaps/Contrast Medium Compatibility testing.
• Provide data from completed studies to the FDA.
• The Business Review Committee and Board will complete their review of the company's business, affairs, strategy, management, and operations.
• The Board will determine actions and plans to be implemented, including potentially seeking a new framework for the relationship with SG Austria.
• Reevaluate programs dependent on SG Austria if a new framework is not successful.
• Actively monitor the common stock's closing bid price and consider all available options, including a reverse stock split, to regain Nasdaq compliance by June 1, 2026.
• Seek additional capital to complete a clinical trial for pancreatic cancer.
• Remediate material weaknesses in internal control over financial reporting (insufficient segregation of duties and management review controls).

Key Dates

Recommendation

PharmaCyte Biotech faces severe headwinds, including substantial and widening net losses, a Nasdaq delisting notice, and a prolonged FDA clinical hold on its primary drug candidate. The company's reliance on a licensed technology with expired patents and know-how residing with a third party (SG Austria) presents a critical long-term risk. While a recent capital raise provides short-term liquidity, the need for significant additional capital for clinical trials, coupled with the high likelihood of dilution and ongoing internal control weaknesses, makes the investment highly speculative with substantial downside risk. The current operational and financial challenges far outweigh any potential future upside, warranting a strong sell recommendation.

Keywords

Biotechnology, Cancer therapy, Pancreatic cancer, Cell-in-a-Box, CypCaps, FDA clinical hold, 10-Q, Nasdaq delisting, Biopharma, Clinical trials, Drug development, Financial results, Warrants, Preferred stock, Capital raise, Corporate governance, Risk factors